TB Treatment Advocacy Groups Discuss TB Test’s Cost In Letter To Manufacturer
The Center for Global Health Policy’s “Science Speaks” blog discusses an open letter to Cepheid Chief Executive Officer John Bishop from the Treatment Action Group and the Global TB Advisory Board regarding the cost of the company’s GeneXpert MTB/RTF rapid TB diagnostic test. “…Cepheid hasn’t responded to requests for comments from Science Speaks, but in comments following a GHDonline discussion Cepheid marketing representative Martin Colla wrote that he would reply to the letter in the ‘near future,'” the blog notes (Barton, 1/27).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.